Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASEL | Q05823 | 3/20 | 1.00 |
| ▸ | BRD4 | O60885 | 11/20 | 0.98 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.70 |
| ▸ | NPC1 | O15118 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | HPGD | P15428 | 2/20 | 0.70 |
| ▸ | RAB9A | P51151 | 2/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | CDKN1A | P38936 | 4/20 | 0.61 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14385807 | 1.00 | RNASEL (1.00) | RNASELBRD4KDM4ENPC1ALDH1A1 | |
| SCHEMBL13005004 | 0.86 | RNASEL (0.76) | RNASELBRD4KDM4ENPC1ALDH1A1 | |
| SCHEMBL14385544 | 0.86 | BRD4 (1.00) | RNASELBRD4KDM4ENPC1ALDH1A1 | |
| SCHEMBL13060422 | 0.86 | RNASEL (0.75) | RNASELBRD4KDM4ENPC1ALDH1A1 | |
| SCHEMBL14385545 | 0.83 | RNASEL (1.00) | RNASELBRD4KDM4ENPC1ALDH1A1 | |
| SCHEMBL13005006 | 0.79 | BRD4 (0.78) | RNASELBRD4KDM4ENPC1ALDH1A1 | |
| SCHEMBL13056437 | 0.76 | BRD4 (0.73) | RNASELBRD4KDM4ENPC1ALDH1A1 | |
| SCHEMBL31401939 | 0.74 | CDKN1A (1.00) | RNASELBRD4KDM4ENPC1ALDH1A1 | |
| SCHEMBL6124893 | 0.73 | HSD17B10 (0.65) | RNASELBRD4KDM4ENPC1ALDH1A1 | |
| SCHEMBL11480397 | 0.70 | BRD4 (0.58) | RNASELBRD4KDM4ENPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158156-A1 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | FLAGSHIP PIONEERING, INC. (US) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158156-A1 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | EFTUD2, SNRPE, DDX21 | RNASEL 40/4885BRD4 2461/4885KDM4E 4551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.